Zhang R - Search Results

1

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.

Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Wang H, et al. Among authors: zhang r. Mol Cancer Ther. 2006 Jun;5(6):1585-92. doi: 10.1158/1535-7163.MCT-06-0094. Mol Cancer Ther. 2006. PMID: 16818518

2

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R. Wang H, et al. Among authors: zhang r. Int J Oncol. 2002 Apr;20(4):745-52. Int J Oncol. 2002. PMID: 11894120

3

Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice.

Wang H, Oliver P, Nan L, Wang S, Wang Z, Rhie JK, Zhang R, Hill DL. Wang H, et al. Among authors: zhang r. Cancer Chemother Pharmacol. 2002 May;49(5):419-24. doi: 10.1007/s00280-002-0433-7. Epub 2002 Mar 8. Cancer Chemother Pharmacol. 2002. PMID: 11976837

4

Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.

Prasad G, Wang H, Agrawal S, Zhang R. Prasad G, et al. Among authors: zhang r. Anticancer Res. 2002 Jan-Feb;22(1A):107-16. Anticancer Res. 2002. PMID: 12017271

5

Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.

Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Wang H, et al. Among authors: zhang r. Int J Oncol. 2002 Jul;21(1):73-80. Int J Oncol. 2002. PMID: 12063552

6

Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial.

Robert F, Spencer SA, Childs HA 3rd, Zhang R, Meredith RF, Wheeler RH, Hawkins MH, Carey D. Robert F, et al. Among authors: zhang r. Lung Cancer. 2002 Aug;37(2):189-99. doi: 10.1016/s0169-5002(02)00029-6. Lung Cancer. 2002. PMID: 12140142 Clinical Trial.

7

Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Wang H, et al. Among authors: zhang r. Mol Med. 2002 Apr;8(4):185-99. Mol Med. 2002. PMID: 12149568 Free PMC article.

8

Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties.

Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R, Agrawal S. Yu D, et al. Among authors: zhang r. Biochem Biophys Res Commun. 2002 Sep 13;297(1):83-90. doi: 10.1016/s0006-291x(02)02127-7. Biochem Biophys Res Commun. 2002. PMID: 12220512

9

Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics.

Zhang R, Wang H. Zhang R, et al. Methods Mol Med. 2003;75:637-54. Methods Mol Med. 2003. PMID: 12407769 No abstract available.

10

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.

Wang H, Yu D, Agrawal S, Zhang R. Wang H, et al. Among authors: zhang r. Prostate. 2003 Feb 15;54(3):194-205. doi: 10.1002/pros.10187. Prostate. 2003. PMID: 12518324

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36,876 results

Search Page

Filters